ArticleFunction (Oxford, England)2026
Orexin facilitates the peripheral chemoreflex in the active phase via corticotropin-releasing hormone neurons that project to the nucleus of the solitary tract.
Article in Function (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The orexin system as a pharmacological target in inflammation: peripheral mechanisms and safety implications.Frontiers in pharmacology · 2026Review
- The bed nucleus of the stria terminalis as a neuromodulatory target for refractory epilepsy.Frontiers in network physiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Projections from the paraventricular nucleus (PVN) of the hypothalamus to the nucleus of the solitary tract (nTS) facilitate the peripheral chemoreflex. A significant proportion of this projection is composed of corticotropin-releasing hormone (CRH) neurons. Orexin neurons in the perifornical hypothalamus augment the peripheral chemoreflex, project to the PVN, and facilitate the hypoxia-induced activation of nTS-projecting CRH neurons. We hypothesized that nTS-projecting CRH neurons are necessary for the full reflex, and that orexin facilitates the reflex via the CRH-nTS pathway. We chemogenetically silenced or activated nTS-projecting CRH neurons during normoxia and acute hypoxia. For each rat, reflex strength was tested in both inactive and active phases as the activity of orexin neurons is phase dependent. Testing was done following vehicle, Compound 21 (1 mg/kg) to activate Gi- or Gq-DREADDs, and after systemic Ox1R blockade (SB-334867; 1 mg/kg). We performed immunohistochemistry to assess how chemogenetic manipulation of nTS-projecting CRH neurons influenced their activation by hypoxia (via cFos). Activating the CRH-nTS pathway had no effect on the chemoreflex in either phase. Silencing the pathway in the active phase, but not inactive phase, reduced the strength of the reflex by ∼50% and prevented further inhibition by Ox1R blockade, suggesting orexin acts via Ox1R on CRH neurons. Pathway silencing reduced the proportion of nTS-projecting CRH neurons activated by hypoxia, consistent with the effects of pathway silencing on the reflex. These data suggest that orexin augments the peripheral chemoreflex in the active phase via the CRH-nTS pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.